Exscientia wants to bring its AI/ML approach into the world of biologics. It's starting with antibodies
Sanofi, Exscientia ink the next AI megadeal, signing terms on a $100M upfront pact with up to 15 drugs on the line CEO Andrew Hopkins tells Endpoints News that the main...
02/18/2023
- READ MORE